BRPI0816345A2 - Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida - Google Patents

Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida

Info

Publication number: BRPI0816345A2
Authority: BR; Brazil
Prior art keywords: xoquinolin; diidro; dimethylethyl; carboxamide; hydroxyphenyl
Prior art date: 2007-09-14

Application number

BRPI0816345-6A2A

Other languages

English (en)

Inventor

John Demattei

Yushi Feng

Cristian Harrison

Adam Looker

Praveen Mudunuri

Stefanie Roeper

Yuegang Zhang

Original Assignee

Vertex Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-14

Filing date

2008-09-15

Publication date

2015-02-24

2008-09-15 Application filed by Vertex Pharma filed Critical Vertex Pharma

2015-02-24 Publication of BRPI0816345A2 publication Critical patent/BRPI0816345A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)

BRPI0816345-6A2A 2007-09-14 2008-09-15 Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida BRPI0816345A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97260507P	2007-09-14	2007-09-14
PCT/US2008/010728 WO2009038683A2 (en)	2007-09-14	2008-09-15	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

Publications (1)

Publication Number	Publication Date
BRPI0816345A2 true BRPI0816345A2 (pt)	2015-02-24

Family

ID=40468681

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816345-6A2A BRPI0816345A2 (pt)	2007-09-14	2008-09-15	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida

Country Status (11)

Country	Link
US (3)	US8163772B2 (pt)
EP (1)	EP2222304A2 (pt)
JP (1)	JP2010540417A (pt)
CN (1)	CN101918366A (pt)
AU (1)	AU2008301907B2 (pt)
BR (1)	BRPI0816345A2 (pt)
CA (1)	CA2699292A1 (pt)
MX (1)	MX2010002974A (pt)
NZ (3)	NZ583848A (pt)
RU (1)	RU2010114732A (pt)
WO (1)	WO2009038683A2 (pt)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA06002567A (es)	2003-09-06	2006-09-04	Vertex Pharma	Moduladores de transportadores con casete de union de atp.
ZA200604578B (en) *	2003-11-14	2008-05-28	Vertex Pharma	Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
CA2810655C (en)	2004-06-24	2013-12-10	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US7999113B2 (en)	2005-08-11	2011-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
PL2404919T3 (pl)	2005-11-08	2014-01-31	Vertex Pharma	Związek heterocykliczny użyteczny jako modulator transporterów zawierających kasetę wiążącą ATP
US7671221B2 (en) *	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
DK1993360T3 (en)	2005-12-28	2017-05-22	Vertex Pharma	SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE
AU2006336504C9 (en) *	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
EP3091011B1 (en)	2006-04-07	2017-12-27	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en) *	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
WO2008141119A2 (en)	2007-05-09	2008-11-20	Vertex Pharmaceuticals Incorporated	Modulators of cftr
JP5389030B2 (ja)	2007-08-24	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
BRPI0816345A2 (pt) *	2007-09-14	2015-02-24	Vertex Pharma	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
DK2217572T3 (da)	2007-11-16	2014-02-03	Vertex Pharma	Isoquinoliner som modulatorer af ATP-bindingskassettetransportører
JP2011506331A (ja) *	2007-12-07	2011-03-03	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の処方物
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
KR20160040745A (ko)	2007-12-07	2016-04-14	버텍스 파마슈티칼스 인코포레이티드	3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태
RS55360B1 (sr)	2007-12-07	2017-03-31	Vertex Pharma	Proces za proizvodnju cikloalkilkarboksiamido-piridin benzoevih kiselina
CA2931134C (en)	2008-02-28	2019-07-30	Vertex Pharmaceuticals Incorporated	Heteroaryl derivatives as cftr modulators
PL2615085T3 (pl)	2008-03-31	2016-02-29	Vertex Pharma	Pochodne pirydynowe jako modulatory CFTR
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
MX2011003249A (es)	2008-09-29	2011-05-19	Vertex Pharma	Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
PL2349263T3 (pl) *	2008-10-23	2014-11-28	Vertex Pharma	Modulatory mukowiscydozowego regulatora przewodnictwa przezbłonowego
HRP20151137T1 (hr)	2009-03-20	2015-11-20	Vertex Pharmaceuticals Incorporated	Postupak za dobivanje modulatora transmembranskog regulatora vodljivosti cistiäśne fibroze
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP4005559B1 (en)	2010-04-07	2025-02-26	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
NZ602795A (en)	2010-04-07	2015-01-30	Vertex Pharma	Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SG10201505700QA (en)	2010-04-22	2015-08-28	Vertex Pharma	Process of producing cycloalkylcarboxamido-indole compounds
EP3138563A1 (en) *	2010-04-22	2017-03-08	Vertex Pharmaceuticals Inc.	Pharmaceutical compositions and administrations thereof
NZ603043A (en)	2010-04-22	2015-02-27	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
HUE047354T2 (hu)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Ivacaftor deuterizált származékai
IN2014KN00885A (pt)	2011-11-08	2015-10-02	Vertex Pharma
RU2644723C2 (ru)	2012-01-25	2018-02-13	Вертекс Фармасьютикалз Инкорпорейтед	Препараты 3-(6-(1-(2, 2-дифторбензо[d][1, 3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
IL265430B2 (en)	2012-02-27	2024-08-01	Vertex Pharma	Pharmaceutical compositions containing a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamode and uses thereof
EP2838882A1 (en) *	2012-04-20	2015-02-25	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR092857A1 (es)	2012-07-16	2015-05-06	Vertex Pharma	Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
EP3470063B1 (en) *	2012-11-02	2025-01-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cftr mediated diseases
ES2730474T3 (es) *	2013-01-31	2019-11-11	Glenmark Pharmaceuticals Ltd	Proceso para la preparación de ivacaftor y solvatos de este
WO2014125506A2 (en)	2013-02-15	2014-08-21	Laurus Labs Private Limited	A process for the preparation of ivacaftor and its intermediates
RU2016122882A (ru)	2013-11-12	2017-12-19	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний
AU2014351028B2 (en)	2013-11-13	2018-07-12	Apotex Inc.	Solid forms of Ivacaftor and processes for the preparation thereof
WO2015128882A2 (en) *	2014-02-27	2015-09-03	Msn Laboratories Private Limited	Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
US10206877B2 (en)	2014-04-15	2019-02-19	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
GB201415381D0 (en)	2014-08-29	2014-10-15	Algipharma As	Inhalable powder formulations of alginate oligomers
MX2017004543A (es)	2014-10-06	2017-10-04	Vertex Pharma	Moduladores de regulador de conductancia transmembranal de fibrosis quística.
CN107250113B (zh) *	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
HRP20211194T1 (hr)	2014-11-18	2021-10-29	Vertex Pharmaceuticals Inc.	Postupak za provođenje testova velike propusnosti putem tekućinske kromatografije visoke djelotvornosti
GB201504878D0 (en)	2015-03-23	2015-05-06	Algipharma As	Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion
AU2016327603B2 (en)	2015-09-25	2021-04-22	Vertex Pharmaceuticals (Europe) Limited	Deuterated CFTR potentiators
GB201517639D0 (en)	2015-10-06	2015-11-18	Algipharma As	Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract
UA124708C2 (uk)	2016-09-30	2021-11-03	Вертекс Фармасьютікалз Інкорпорейтед	Модулятор муковісцидозного регулятора трансмембранної провідності, фармацевтичні композиції, способи лікування та спосіб отримання модулятора
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
MA54105A (fr)	2017-06-08	2021-09-15	Vertex Pharma	Méthodes de traitement de la fibrose kystique
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
WO2019028228A1 (en)	2017-08-02	2019-02-07	Vertex Pharmaceuticals Incorporated	PROCESSES FOR THE PREPARATION OF PYRROLIDINE COMPOUNDS
AU2018351533B2 (en)	2017-10-19	2023-02-02	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
BR112020010335A2 (pt)	2017-12-01	2020-11-10	Vertex Pharmaceuticals Incorporated	processos para produzir moduladores de regulador de condutância de transmembrana de fibrose cística
US11465985B2 (en)	2017-12-08	2022-10-11	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
WO2019161078A1 (en)	2018-02-15	2019-08-22	Vertex Pharmaceuticals Incorporated	Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es)	2019-04-03	2020-10-30	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020212898A1 (en)	2019-04-18	2020-10-22	Callidus Research Laboratories Pvt Limited	Pharmaceutical oral liquid solution of ivacaftor
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
JP7752106B2 (ja)	2019-08-14	2025-10-09	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒモジュレータの結晶形態
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US11384054B2 (en)	2020-10-22	2022-07-12	Scinopharm Taiwan, Ltd.	Crystalline form of ivacaftor and a process for preparing the same
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
JP2023552828A (ja)	2020-12-10	2023-12-19	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0201669D0 (sv) *	2002-06-03	2002-06-03	Pharmacia Ab	New formulation and use thereof
CA2810655C (en)	2004-06-24	2013-12-10	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
DK1993360T3 (en) *	2005-12-28	2017-05-22	Vertex Pharma	SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOQUINOLIN-3-CARBOXAMIDE
BRPI0816345A2 (pt) *	2007-09-14	2015-02-24	Vertex Pharma	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en) *	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
HRP20151137T1 (hr) *	2009-03-20	2015-11-20	Vertex Pharmaceuticals Incorporated	Postupak za dobivanje modulatora transmembranskog regulatora vodljivosti cistiäśne fibroze

2008
- 2008-09-15 BR BRPI0816345-6A2A patent/BRPI0816345A2/pt not_active IP Right Cessation
- 2008-09-15 US US12/283,702 patent/US8163772B2/en active Active
- 2008-09-15 AU AU2008301907A patent/AU2008301907B2/en not_active Ceased
- 2008-09-15 RU RU2010114732/04A patent/RU2010114732A/ru not_active Application Discontinuation
- 2008-09-15 NZ NZ583848A patent/NZ583848A/en not_active IP Right Cessation
- 2008-09-15 WO PCT/US2008/010728 patent/WO2009038683A2/en not_active Ceased
- 2008-09-15 CA CA2699292A patent/CA2699292A1/en not_active Abandoned
- 2008-09-15 NZ NZ620027A patent/NZ620027A/en not_active IP Right Cessation
- 2008-09-15 NZ NZ600865A patent/NZ600865A/en not_active IP Right Cessation
- 2008-09-15 EP EP08832069A patent/EP2222304A2/en not_active Withdrawn
- 2008-09-15 JP JP2010524884A patent/JP2010540417A/ja active Pending
- 2008-09-15 MX MX2010002974A patent/MX2010002974A/es unknown
- 2008-09-15 CN CN200880116588XA patent/CN101918366A/zh active Pending
2012
- 2012-03-06 US US13/413,327 patent/US8362253B2/en active Active
- 2012-12-14 US US13/714,911 patent/US8623894B2/en active Active

Also Published As

Publication number	Publication date
CA2699292A1 (en)	2009-03-26
NZ600865A (en)	2014-01-31
US20120165372A1 (en)	2012-06-28
US8362253B2 (en)	2013-01-29
US20090099230A1 (en)	2009-04-16
JP2010540417A (ja)	2010-12-24
EP2222304A2 (en)	2010-09-01
CN101918366A (zh)	2010-12-15
MX2010002974A (es)	2010-07-29
AU2008301907B2 (en)	2014-02-20
US8623894B2 (en)	2014-01-07
NZ583848A (en)	2012-07-27
US20130109717A1 (en)	2013-05-02
AU2008301907A1 (en)	2009-03-26
WO2009038683A3 (en)	2010-08-26
WO2009038683A2 (en)	2009-03-26
US8163772B2 (en)	2012-04-24
NZ620027A (en)	2015-05-29
RU2010114732A (ru)	2011-10-20

Publication	Publication Date	Title
BRPI0816345A2 (pt)	2015-02-24	Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida
EP1993360A4 (en)	2010-12-01	SOLID FORMS OF N- [2,4-BIS (1,1-DIMETHYLETHYL) -5-HYDROXYPHENYL] -1,4-DIHYDRO-4-OXOCHINOLINE-3-CARBOXAMIDE
CR20130381A (es)	2013-09-12	Formas farmacéuticas con propiedades farmacocinéticas mejoradas
BRPI0714539A2 (pt)	2014-02-25	"formas farmacêuticas"
HUE035931T2 (hu)	2018-06-28	N-[2,4-bis(1,1-dimetiletil)-5-hidroxipenil]-1,4-dihidro-4-oxokinolin-3-karboxamid gyógyszerészeti készítménye és annak alkalmazása
IL244442A0 (en)	2016-04-21	Compounds of converted acylanilides and their use
DK2464337T4 (da)	2024-07-22	Tabletformulering af N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid til anvendelse til behandling af cystisk fibrose
BRPI0920082A2 (pt)	2019-09-24	forma de dosagem oral de acetaminofeno/tramadol com liberação estendida.
BRPI0909084A2 (pt)	2015-08-11	Composição líquida, e, composto de peptídeo.
BRPI0813449A2 (pt)	2014-12-23	Formas de dosagem sólida ou semissólida de liberação modificada.
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
EP2371793A4 (en)	2012-08-01	PROCESS FOR PREPARING 1,1-DICHLORO-2,3,3,3-TETRAFLUORO-PROPANE AND 2,3,3,3-TETRAFLUORPROPENE
BRPI0818373A2 (pt)	2017-05-16	compostos de pelicetal, síntese e aplicações
DK2010159T3 (da)	2012-10-22	Paracetamoltabletter med hurtig frigivelse
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0807220B1 (pt)	2016-11-16	composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
EP2127674A4 (en)	2011-04-27	MEDIUM TO PROMOTE THE AFTERWORKING OF HAIR
IL200514A0 (en)	2010-04-29	Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
BRPI0812015A2 (pt)	2014-11-18	Membro de reforço de borracha e produto de borracha utilizando o mesmo.
BRPI0911772A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso do composto.
EP2283352A4 (en)	2012-03-14	Acetaminophen TEST PROCEDURE
ITMI20071261A1 (it)	2008-12-23	Procedimento per la preparazione di cinacalcet
CR10685A (es)	2009-05-22	Proceso para estabilizaciuon de famotidina
BR112012002311A2 (pt)	2016-05-31	composto, composição farmacêutica, e, uso do composto.
BRPI0810776A2 (pt)	2014-10-07	Uso de uma dispersão aquosa, dispersão aquosa, e, composição cosmética.

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.